# Regeneron also earns spot on Dow Jones Best-in-Class North America Index for six consecutive years.

*biotech · news · 2026-05-08 · GlobeNewswire*

## Key points

- Regeneron will provide its new gene therapy for genetic hearing loss for free in the U.S.
- Regeneron introduced new science-led 2030 responsibility goals detailed in its 2025 Responsibility Report.
- Together for CHANGE™ aims to genetically sequence 500,000 volunteers of African ancestry for genomics research.
- Regeneron ranks in the top 10% of its industry on major ESG ratings such as S&P Global and ISS ESG.

**Companies:** Regeneron Pharmaceuticals, Inc.
**Countries:** United States

[Read the full story on GlobeNewswire](https://www.globenewswire.com/news-release/2026/05/08/3290991/0/en/regeneron-named-to-dow-jones-best-in-class-world-index-for-global-responsibility-leadership-for-seven-consecutive-years.html)

---

Canonical: https://newsio.io/n/b2e67aef-1f0c-4c6c-a0e2-001e717e29d4/regeneron-also-earns-spot-on-dow-jones-best-in-class-north-america-index-for-six
Summarized by Newsio from GlobeNewswire. https://newsio.io/how-it-works